THERAPY MONITORING IN TREATMENT WITH BINDING AGENT AGAINST ADRENOMEDULLIN (ADM) Russian patent published in 2022 - IPC G01N33/53 G01N33/68 

FIELD: biotechnology.

SUBSTANCE: invention relates to biotechnology, in particular to a method for therapy monitoring in a subject. The subject is undergoing treatment with an agent binding anti-adrenomedullin (hereinafter – ADM), selected from a group including an antibody, an antibody fragment and/or a non-Ig-frame binding to SEQ ID NO.1. A level of a fragment of pre-pro-adrenomedullin selected from mid-regional pro-adrenomedullin (MR-proADM), C-terminal pro-adrenomedullin (CT-proADM) and/or peptide of 20 N-terminal amino acids of pro-adrenomedullin (PAMP), or their fragments in biological fluid is determined. To determine the level of the fragment of pre-pro-adrenomedullin, at least one binding agent is bound to an area inside an amino acid sequence selected from SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively. The level of the specified fragment of pre-pro-adrenomedullin is correlated with a clinical/medical condition of the subject and/or the risk of unfavorable outcome, and/or the need for regulation of therapeutic measures.

EFFECT: invention allows for monitoring of the risk of unfavorable outcome for a subject directly in the treatment with an antibody against ADM.

15 cl, 6 dwg, 2 tbl, 3 ex